thank you and excellent summary

This reminds me of the presentation Don made to the Biotech Showcase in January of 2015.  At that point the share price was around 40 cents and they had just figured out the "spectacular" RRR for the subgroups in the combined phase 2.  The conclusion was that new targets were called for and thus BetOnMace came about.  Years later it seems we are back to that point with yet another set of targets...eGFR below 60 and congestive heart failure...and perhaps vascular dementia.

This time, the money is probably not there for another phase 3.  I think the best outcome would be to sell the company outright...but what do I know?